WHO Regional Office for Africa


The Ministry of Health of Cote d’Ivoire today confirmed the country’s first case of Ebola since 1994. This came after the Institut Pasteur in Cote d’Ivoire confirmed the Ebola Virus Disease in samples collected from a patient, who was hospitalized in the commercial capital of Abidjan, after arriving from Guinea.

Initial investigations found that the patient had travelled to Cote d’Ivoire by road and arrived in Abidjan on 12 August. The patient was admitted to a hospital after experiencing a fever and is currently receiving treatment.

Guinea experienced a four-month long Ebola outbreak, which was declared over on the 19 June 2021. There is no indication that the current case in Cote d’Ivoire is linked to the earlier outbreak in Guinea. Further investigation and genomic sequencing will identify the strain and determine if there is a connection between the two outbreaks.

This year Ebola outbreaks have been declared in the Democratic Republic of the Congo and Guinea, but it is the first time an outbreak has occurred in a large capital city such as Abidjan since the 2014–2016 West Ebola outbreak.

“It is of immense concern that this outbreak has been declared in Abidjan, a metropolis of more than 4 million people,” said Dr Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa. “However, much of the world’s expertise in tackling Ebola is here on the continent and Cote d’Ivoire can tap into this experience and bring the response to full speed. The country is one of the six that WHO has supported recently to beef up their Ebola readiness and this quick diagnosis shows preparedness is paying off.”

WHO is helping to coordinate cross-border Ebola response activities and 5000 Ebola vaccines doses which the organization helped secure to fight the outbreak in Guinea are now being transferred to Cote d’Ivoire, following an agreement between the ministries of health of Cote d’Ivoire and Guinea. An aircraft is departing Abidjan soon to collect the vaccines which will be used to vaccinate people at high risk, including health workers, first responders and contacts of confirmed cases.

WHO staff based in Cote d’Ivoire are supporting the investigation into the case. In addition, a multidisciplinary team of WHO experts covering all key response areas will be deployed rapidly to the field. They will help with ramping up infection prevention and control of health facilities, diagnostics, contact tracing, treatment and reaching out to communities to ensure they take a key role in the response.

Cote d’Ivoire declared the outbreak in line with International Health Regulations and WHO does not advise any travel restrictions to and from the country.

While countries are focused on the COVID-19 response, they should strengthen their preparedness for potential Ebola cases. 

While Cote d’Ivoire borders Guinea and Liberia which were struck hard by the 2014–2016 West Africa Ebola outbreak, the country has had no confirmed cases reported since 1994, when an outbreak among chimpanzees infected a scientist.

Ebola is a severe, often fatal illness affecting humans and other primates. Case fatality rates have varied from 25% to 90% in past outbreaks. There is now effective treatment available and if patients receive treatment early, as well as supportive care, their chances of survival improve significantly.

Distributed by APO Group on behalf of WHO Regional Office for Africa.

Send us your press releases to pressrelease.zawya@refinitiv.com


© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.